← Back to Clinical Trials
Recruiting Phase 2, Phase 3 NCT06801522

NCT06801522 Adrenaline Nasal Pack vs Xylometazoline Nasal Drops During Nasotracheal Intubation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06801522
Status Recruiting
Phase Phase 2, Phase 3
Sponsor Shaheed Mohtarma Benazir Bhutto Institue of Trauma
Condition Nasal Bleeding
Study Type INTERVENTIONAL
Enrollment 70 participants
Start Date 2024-12-01
Primary Completion 2025-03

Trial Parameters

Condition Nasal Bleeding
Sponsor Shaheed Mohtarma Benazir Bhutto Institue of Trauma
Study Type INTERVENTIONAL
Phase Phase 2, Phase 3
Enrollment 70
Sex ALL
Min Age 18 Years
Max Age 60 Years
Start Date 2024-12-01
Completion 2025-03
Interventions
0.1% xylometazoline nasal dropsAdrenaline nasal pack

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this trial is to compare efficacy of xylometazoline nasal drops and adrenaline nasal pack in participants undergoing elective oromaxillofacial surgeries. The main question aim to answer is xylometazoline nasal drops better than adrenaline nasal packing in terms of nasal bleeding during nasotracheal intubation. Researchers are comparing 2 groups of participants. Participants in group Xylometazoline are receiving 0.1% xylometaxoline nasal drops. Participants in group Adrenaline are receiving adrenaline nasal packing.

Eligibility Criteria

Inclusion Criteria: * ASA 1 and 2 * Age group between 18-60 years * Mallampati score 1 and 2 * Either gender * Participants who undergo elective oromaxillofacial surgery Exclusion Criteria: * Lack of consent * Participants with anticipated difficult airway * Participants receiving anticoagulant therapy * History of nasal abnormality (nasal surgery, trauma, polyp, obstruction) * History of repeated epistaxis * History of uncontrolled hypertension, diabetes, pregnancy, and any other cardiac or cerebral events.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology